Proto Labs COO sells shares, exercises options
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported a series of transactions in company common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported a series of transactions in company common stock. On May 11–12, 2026, he sold a total of 23,463 shares in open-market sales at weighted average prices generally between about $67 and $71 per share, under a pre-arranged Rule 10b5-1 trading plan adopted August 15, 2025. Over the same two days, he exercised employee stock options covering 14,960 shares at exercise prices of $33.52, $33.84, $39.61 and $59.40 per share, converting derivative awards into common stock. Following these transactions, he directly holds 18,683 Proto Labs shares.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
15 txns
Insider
Kenison Michael R.
Role
Chief Operations Officer
Sold
23,463 shs ($1.64M)
Approx. gross sale proceeds
$1.64M
Approx. exercise cost
$617K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 1,928 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) | 1,557 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) | 4,042 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,928 | $33.84 | $65K |
| Exercise | Common Stock | 1,557 | $39.61 | $62K |
| Exercise | Common Stock | 4,042 | $59.40 | $240K |
| Sale | Common Stock | 1,613 | $67.5807 | $109K |
| Sale | Common Stock | 4,198 | $68.6971 | $288K |
| Sale | Common Stock | 3,576 | $69.7823 | $250K |
| Sale | Common Stock | 6,643 | $70.2958 | $467K |
| Exercise | Employee Stock Option (right to buy) | 3,756 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) | 3,677 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,756 | $33.84 | $127K |
| Exercise | Common Stock | 3,677 | $33.52 | $123K |
| Sale | Common Stock | 7,433 | $70.2612 | $522K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 10,380 contracts (Direct);
Common Stock — 18,683 shares (Direct)
Footnotes (10)
- F1. These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025.
- F2. Reflects the weighted average price of 7,433 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 11, 2026, with sale prices ranging from $70.00 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3. Reflects the weighted average price of 1,613 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $67.06 to $68.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4. Reflects the weighted average price of 4,198 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $68.10 to $69.0425 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5. Reflects the weighted average price of 3,576 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $69.13 to $70.1181 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6. Reflects the weighted average price of 6,643 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $70.13 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F7. 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested.
- F8. 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested.
- F9. 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested.
- F10. 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested.
Key Figures
Shares sold: 23,463 shares
Options exercised: 14,960 shares
Post-trade holdings: 18,683 shares
+4 more
7 metrics
Shares sold
23,463 shares
Total common stock sold May 11–12, 2026
Options exercised
14,960 shares
Total shares from option exercises May 11–12, 2026
Post-trade holdings
18,683 shares
Common shares directly owned after latest transaction
Sale price example
$70.2612 per share
Weighted average price for 7,433 shares sold May 11, 2026
Sale price range example
$70.00–$70.57 per share
Price range for 7,433 shares sold May 11, 2026
Exercise price (option)
$59.40 per share
Exercise price for 4,042 options into common stock
Lower exercise price
$33.52 per share
Exercise price for 3,677 options into common stock
Key Terms
10b5-1 plan, weighted average price, Employee Stock Option (right to buy), derivative security, +1 more
5 terms
10b5-1 plan financial
"These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025."
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
weighted average price financial
"Reflects the weighted average price of 7,433 shares of common stock of Proto Labs Inc. sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option (right to buy) financial
"security_title": "Employee Stock Option (right to buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Proto Labs (PRLB) report for Michael R. Kenison?
Proto Labs reported that Chief Operations Officer Michael R. Kenison sold 23,463 common shares and exercised options for 14,960 shares on May 11–12, 2026. These were open-market sales and derivative exercises disclosed in a Form 4 insider trading report.
What stock options did the Proto Labs (PRLB) COO exercise in this filing?
Michael R. Kenison exercised employee stock options covering 14,960 shares of Proto Labs common stock. The options had exercise prices of $33.52, $33.84, $39.61 and $59.40 per share, converting derivative awards into directly held common shares across May 11–12, 2026.
Were the Proto Labs (PRLB) COO’s stock sales made under a 10b5-1 plan?
Yes. A footnote states the Proto Labs COO’s shares were acquired and sold pursuant to a Rule 10b5-1 trading plan adopted on August 15, 2025. Such pre-arranged plans schedule trades in advance, reducing the significance of short-term market timing.
What do the weighted average price footnotes mean in the Proto Labs (PRLB) Form 4?
The weighted average price footnotes explain that each reported sale aggregates multiple trades within a price range. For each share group, the Form 4 lists a single average price and notes that detailed trade-by-trade prices are available on request from Proto Labs, regulators or shareholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates